In 2019, the Government published the first of four five-year national action plans (NAP), aimed at tackling antimicrobial resistance (AMR) within and beyond our own borders. This plan is available at the following link:<\/p>
https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024<\/a><\/p> We are now in the process of developing the second five-year NAP, which will run from 2024 to 2029. It will be designed to ensure progress is maintained towards delivering our 20-year vision on AMR, in which resistance is effectively contained and controlled by 2040. Further information on the 20-year vision is available at the following link:<\/p> https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance<\/a><\/p> The 2024 to 2029 AMR NAP is being co-developed across the Government, its agencies, and the administrations in Scotland, Wales, and Northern Ireland, with support from a wide range of external stakeholders, and informed by the responses to the Call for Evidence. The NAP is expected to be published in 2024.<\/p> The 2024 to 2029 AMR NAP will build on the achievements of the 2019 to 2024 NAP, whilst recognising where there is more to do, and will be aligned with global plans and frameworks for action.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-23T12:31:44.14Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-17", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antimicrobials: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when she plans to publish the next action plan for antimicrobial resistance.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "22343"}
, {"_about" : "http://data.parliament.uk/resources/1701128", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1701128/answer", "answerText" : {"_value" : " As described in the answer of 14 March 2022 to Question 133232, progress towards the target of halving healthcare-associated Gram-negative bloodstream infections (GNBSI) has proved very challenging, in part due to the diverse nature of the underlying causes of these infections. Data on the incidence of these infections in England is published quarterly by the UK Health Security Agency, and is available at the following link:<\/p> We are currently developing the 2024 to 2029 antimicrobial resistance national action plan. We anticipate that in the delivery of this plan, we will continue to focus on GNBSI, building on lessons learnt over the past five years.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-23T15:47:27.15Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Answer of 14 March 2022 to Question 133232 on Antibiotics: Drug Resistance and to the policy paper entitled UK five-year action plan for antimicrobial resistance: 2019 to 2024, published on 24 January 2019, what recent progress her Department has made on halving healthcare-associated Gram-negative blood stream infections.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "21728"}
, {"_about" : "http://data.parliament.uk/resources/1695234", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1695234/answer", "answerText" : {"_value" : " The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).<\/p> <\/p> On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.<\/p> <\/p> Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-20", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-20T17:11:23.963Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-12", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes: Medical Equipment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "18214"}
, {"_about" : "http://data.parliament.uk/resources/1694161", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1694161/answer", "answerText" : {"_value" : " The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.<\/p> <\/p> The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-03-13", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-03-13T16:04:37.597Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-03-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes: Medical Equipment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "17412"}
, {"_about" : "http://data.parliament.uk/resources/1691367", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1691367/answer", "answerText" : {"_value" : " Standard care for type 1 diabetes involves regularly measuring blood glucose levels by self-monitoring, blood testing, or by using a continuous glucose monitor, real-time or intermittently scanned.<\/p> The NHS Long Term Plan committed that 20% of people with type 1 diabetes would benefit from life changing flash glucose monitors. Data to quarter three of 2022/23 shows that 73% of people with type 1 diabetes were prescribed flash glucose monitoring, against the 20% target.<\/p> In March 2023 the National Institute for Health and Care Excellence (NICE) recommended that insulin dependent patients with type 2 diabetes should also benefit from flash or continuous glucose monitoring devices. We are now starting to see a growth in prescribing within the type 2 diabetes patient group.<\/p> On 19 December 2023 the NICE published its final recommendation on the hybrid closed loop system. The NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be the first to be offered a hybrid closed loop system, as part of a five-year roll-out plan. Access to hybrid closed loop systems will be through a five-year phased roll out, in line with NHS England\u2019s implementation plans.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2024-02-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-29T14:08:08.19Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Diabetes: Medical Equipment"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether her Department plans to take steps to ensure that every person with diabetes has access to medical technology that helps them manage their condition.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "15459"}
, {"_about" : "http://data.parliament.uk/resources/1675649", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1675649/answer", "answerText" : {"_value" : " We have no specific plans to make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease. However, in England, NHS England is working with front-line clinical experts, patient representative groups and leading charities, including Crohn\u2019s and Colitis UK, to improve diagnosis and treatment of inflammatory bowel disease (IBD). This includes a new IBD RightCare scenario, which, when published, will set out high-quality joined-up care at every point of the patient journey, as well as data packs for local commissioners.<\/p> In addition, the Getting it Right First Time specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country. Information on trends in the incidence rates of Crohn\u2019s disease and ulcerative colitis is not held.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2023-12-11", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "5382"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-12-11T17:45:42.52Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-12-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Inflammatory Bowel Disease: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "5381"}
, {"_about" : "http://data.parliament.uk/resources/1675650", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1675650/answer", "answerText" : {"_value" : " We have no specific plans to make an assessment of the potential merits of implementing a UK-wide blueprint for inflammatory bowel disease. However, in England, NHS England is working with front-line clinical experts, patient representative groups and leading charities, including Crohn\u2019s and Colitis UK, to improve diagnosis and treatment of inflammatory bowel disease (IBD). This includes a new IBD RightCare scenario, which, when published, will set out high-quality joined-up care at every point of the patient journey, as well as data packs for local commissioners.<\/p> In addition, the Getting it Right First Time specialty report on gastroenterology, published in September 2021, sets out actions and recommendations for the National Health Service to improve patient care and ensure consistency of care across the country. Information on trends in the incidence rates of Crohn\u2019s disease and ulcerative colitis is not held.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4044", "label" : {"_value" : "Biography information for Andrew Stephenson"}
}
, "answeringMemberConstituency" : {"_value" : "Pendle"}
, "answeringMemberPrinted" : {"_value" : "Andrew Stephenson"}
, "dateOfAnswer" : {"_value" : "2023-12-11", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "5381"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-12-11T17:45:42.597Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2023-12-05", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Inflammatory Bowel Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what data her Department holds on trends in the incidence rates of (a) Crohn\u2019s and (b) Ulcerative Colitis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "5382"}
, {"_about" : "http://data.parliament.uk/resources/1672411", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1672411/answer", "answerText" : {"_value" : " The Department and the Medicines and Healthcare products Regulatory Agency (MHRA) are members of the GLP1-RA Incident Management Team. Risk management in relation to the advertising and sale of these medicinal products is a standing item for discussion.<\/p> MHRA is obliged to consider complaints received about the advertisement of prescription-only medicines (POMs) to the public. Advertising investigations are carried out on a case-by-case basis, having regard to the circumstances of the particular case. Completed advertising investigations leading to correction of advertising materials are available at the following link:<\/p>
https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data<\/a><\/p>
Incidence of the three main healthcare-associated GNBSI organisms, E. coli, klebsiella pneumoniae, and pseudomonas aeruginosa, has fluctuated between 2019 and 2024, including a sharp decline in the incidence of E. coli seen during the COVID-19 pandemic. However, overall, the total incidence of healthcare associated GNBSI remains significantly above the target.<\/p>